Table 1 Clinical characteristics of RA-a and RA-r patients
Variable | RA-a (n = 17) | RA-r (n = 17) |
|---|---|---|
Age, years, median (IQR) | 57 (54 to 63.5) | 53.5 (44 to 57.5) |
Female, n (%) | 16 (94) | 13 (76.5) |
Disease duration, years, median (IQR) | 12.5 (6 to 20) | 10 (6 to 16.5) |
Disease activity in 28 joints (DAS28) score, median (IQR) | 3.4 (3 to 4.4) | 2 (1.7 to 2.4) |
Rheumatoid factor-positive, n(%) | 16 (94) | 16 (94) |
Anti-citrullinated peptide antibodies-positive, n (%) | 14 (82) | 14 (82) |
Methotrexate, n (%) | 17 (100) | 17 (100) |
Prednisone ≤5 mg/day, n (%) | 11 (65) | 4 (24) |
Leflunomide, n (%) | 2 (12) | 3 (18) |
Hydroxychloroquine, n (%) | 2 (12) | 4 (24) |